Overview

Evaluate the Safety, Tolerability, Dose-finding and Expansion of Intratumoral Injection of JCXH-211 Injection

Status:
Not yet recruiting

Trial end date:
2025-08-24

Target enrollment:

Participant gender:

Summary

This study is an open-label, dose-escalation and dose-expansion phase I clinical study. The study is divided into Phase 1a and Phase 1b.

Phase:

Phase 1

Details

Lead Sponsor:

Immorna Biotherapeutics, Inc.